Prognostic impact of Cyfra21-1 and other serum markers in completely resected non-small cell lung cancer

Lung Cancer

Volumn 36, Issue 3, 2002, Pages 265-270

  Reinmuth, Niels ^a,c   Brandt, Burkhard ^a   Semik, Michael ^a   Kunze, Wolf Peter ^b   Achatzy, Richard ^b   Scheld, Hans H ^a   Broermann, Petra ^a   Berdel, Wolfgang E ^a   Macha, Hans N ^b   Thomas, Michael ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b Departments of Thoracic Surgery and Pneumology   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Cyfra21 1; Early stage disease; Long term follow up; Non small cell lung cancer; Prognostic factor; Prospective study

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; NEURON SPECIFIC ENOLASE; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; REGRESSION ANALYSIS;

ANTIGENS, NEOPLASM; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; FOLLOW-UP STUDIES; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; PHOSPHOPYRUVATE HYDRATASE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SERPINS; SURVIVAL ANALYSIS; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL;

EID: 0036257505     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00009-0     Document Type: Article

References (32)

1. Study of prognostic predictors for non-small cell lung cancer
2. Revisions in the international system for staging lung cancer
3. Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung
4. Evaluation of a new tumour marker in patients with non-small-cell lung cancer: Cyfra 21.1
5. Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in resectable non-small-cell lung cancer
6. Clinical significance of a multiple biomarker assay in patients with lung cancer. A study with logistic regression analysis
7. Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer
8. Neuron-specific enolase in the diagnosis and therapy monitoring of lung cancer: A comparison with CEA, TPA, ferritin and calcitonin
9. Serum neuron-specific enolase: A marker for disease extent and response to therapy of small-cell lung cancer
10. Cyfra 21-1, neuron specific enolase and prognosis of non-small cell lung cancer: Prospective study in 621 patients
11. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma
12. The catalog of human cytokeratins: Patterns of expression in normal epithelia, tumors and cultured cells
13. CYFRA 21-1. A new marker in lung cancer
14. Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in nonsmall cell lung carcinoma: Does the combined use of cytokeratin markers give any additional information?
15. Cytokeratins as serum markers in lung cancer: A comparison of CYFRA 21-1 and TPS
16. The clinical value of Cyfra 21-1 estimation for lung cancer patients
17. Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: A prospective study of 116 patients
18. Non-parametric estimation from incomplete observations
19. Martingale based residuals for surviving models
20. Different cutoff values of Cyfra 21-1 for cavitary and noncavitary lung cancers
21. Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer
22. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer
23. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer
24. Determinants of long term survival after surgery for cancer of the lung: A population-based study
25. Prognostic factors in lung cancer: Tables and comments
26. The role of chemotherapy in early-stage (stages I and II) resectable non-small cell lung cancer
27. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer
28. Preresectional chemotherapy in stage IIIA non-small-cell lung cancer: A 7-year assessment of a randomized controlled trial
29. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer
30. Long-term follow-up of patients enrolled in a randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer
31. Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer
32. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer